Drug class

Diet Aids

"Diet Aids" is an informal, consumer-oriented category rather than a formal, standard therapeutic drug class recognized by regulatory bodies like the FDA. Read more about Diet Aids

66 drugs in this class 32 manufacturers

Advertisement

Drugs in Diet Aids

Showing 1–9 of 66 drugs

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+1
Lannett Company

BENZPHETAMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)
KVK-TECH, INC.

DIETHYLPROPION HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)
Lannett Company

DIETHYLPROPION HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)
KVK-TECH, INC.

PHENDIMETRAZINE TARTRATE

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)
C.O. Truxton

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+1
Lannett Company

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+1
KVK-TECH, INC.

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+1
MUTUAL PHARM CO
Filter & compare in the drug finder → Opens the drug finder with Diet Aids preselected. Add indication or manufacturer filters there.

About Diet Aids.

"Diet Aids" is an informal, consumer-oriented category rather than a formal, standard therapeutic drug class recognized by regulatory bodies like the FDA.

In medical practice and clinical pharmacology, these agents are formally classified as anti-obesity agents, anorexiants, or weight-loss medications.

They promote weight reduction through diverse mechanisms, including central nervous system appetite suppression, stimulation of satiety pathways via incretin mimetics, or inhibition of gastrointestinal fat absorption.

These products are primarily indicated for chronic weight management in clinical obesity or overweight associated with metabolic and cardiovascular comorbidities.